Kidney360 is ASN's first open access, online only, general kidney journal that includes content from all disciplines of kidney science. Published content includes both clinical and basic science papers. Kidney360 promises to bring you the same high-quality peer-review you've come to expect from ASN's publications.

Kidney360
Claim This Podcastby American Society of Nephrology
Podcast Authority
Beta
Podcast Overview
Kidney360 is ASN's first open access, online only, general kidney journal that includes content from all disciplines of kidney science. Published content includes both clinical and basic science papers. Kidney360 promises to bring you the same high-quality peer-review you've come to expect from ASN's publications.
Language
🇺🇲
Publishing Since
1/30/2020
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
Podcast Authority
Beta
Recommendations available
Unlock the full report to see detailed tips
Recommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Kidney360
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes

May 28, 2026
Kidney Function Decline in Sickle Cell Disease: Associations with Renin Angiotensin System Inhibitors
Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.

April 30, 2026
Impact of Loop Diuretics on Long-Term Kidney Outcome: A Post-Hoc Analysis of the STOP-ACEi Trial
This podcast discusses a post hoc analysis of the STOP-ACEi trial, examining whether baseline loop diuretic use modifies the effect of Renin–Angiotensin System Inhibitors in advanced CKD.

February 26, 2026
Facilitators and Barriers to Patient Enrollment in the AV Access Trial of Vascular Access Outcomes: A Qualitative Study
This episode highlights data from a qualitative substudy of the AV Access trial, a randomized controlled trial studying outcomes of older adults who are receiving hemodialysis with a central venous catheter.
60 total episodes available
Similar Podcasts
Discover related shows you might enjoy

Clinical Journal of the American Society of Nephrology (CJASN)
American Society of Nephrology

Journal of the American Society of Nephrology (JASN)
American Society of Nephrology

ASN Podcast
American Society of Nephrology

KDIGO Conversations in Nephrology
KDIGO Communications

The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast

Core IM | Internal Medicine Podcast
Core IM Team

Annals On Call Podcast
American College of Physicians

JAMA Clinical Reviews
JAMA Network

GN in Ten
International Society of Glomerular Disease

Harrison's PodClass: Internal Medicine Cases and Board Prep
AccessMedicine

NEJM This Week
NEJM Group

BMJ Best Practice Podcast
BMJ Group

What Now? with Trevor Noah
Trevor Noah

JAMA Medical News
JAMA Network

The BMJ Podcast
The BMJ
Deep-dive analytics for Kidney360
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Kidney360?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.